Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

g, and an initial response rate of approximately 70 percent to this type of chemotherapy regimen can be anticipated. In spite of initial response rates, recurrence rates among ovarian cancer patients are high, and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc. Other trademarks are the property of their respective owners.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy and commercial potential of SNS-595, planned additional clinical testing and development efforts and the anticipated timing of the completion of enrollment in the ongoing Phase 2 clinical trial and the announcement of clinical results. Words such as "look forward," "suggests," "may," "plans," "expects," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Laboratories, Inc. (Nasdaq: CBRX ) ("Columbia" ... the three and six-month periods ended June 30, ... from the contribution of the Molecular Profiles services ... an anticipated and temporary decline in product revenues ... in one high-volume, high-margin market. Throughout the renewal ...
(Date:7/31/2014)... 31, 2014 Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced that the Company will ... its partner Asahi Kasei Pharma Corporation (Asahi Kasei). ... submission of a regulatory application to the Japanese ... ® (collagenase clostridium histolyticum) for the treatment ...
(Date:7/30/2014)...  There is still time to share your ... Annual Institute for Supply Management ® – ... Management is open for submissions.  The annual competition ... of supply management by recognizing supply management organizations ... practices.  Entries are due August 22, 2014. ...
Breaking Medicine Technology:Columbia Laboratories Reports Second Quarter 2014 Financial Results 2Columbia Laboratories Reports Second Quarter 2014 Financial Results 3Columbia Laboratories Reports Second Quarter 2014 Financial Results 4Columbia Laboratories Reports Second Quarter 2014 Financial Results 5Columbia Laboratories Reports Second Quarter 2014 Financial Results 6Columbia Laboratories Reports Second Quarter 2014 Financial Results 7Columbia Laboratories Reports Second Quarter 2014 Financial Results 8Columbia Laboratories Reports Second Quarter 2014 Financial Results 9Columbia Laboratories Reports Second Quarter 2014 Financial Results 10Columbia Laboratories Reports Second Quarter 2014 Financial Results 11Columbia Laboratories Reports Second Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2
... Ltd. is pleased to announce that the Phase 2a clinical ... completed by January 21, 2011. Our company focuses ... market of androgenetic alopecia treatment and has developed a new ... androgenetic alopecia treatment was performed in 48 patients with mild-to-moderate ...
... 21, 2011 Cardiac Science Corporation , a ... and diagnostic cardiac monitoring devices that connect ... information systems, today announced it has completed certification with ... its HeartCentrix cardiology device connectivity solution for its resting ...
Cached Medicine Technology:R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia 2R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5
(Date:7/31/2014)... 2014 Many lawyers take up the law ... correct injustices, and preserve the rule of law. Upholding these ... lauded as crusading and exemplary by some, but reckless and ... whose seed might be planted within the legal system itself, ... punishment for an attorney - a referral to the bar's ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... managed IT solutions firm based in New York City, ... cabling infrastructure for the midtown Manhattan headquarters of a ... in corporate and investment banking. , Chico Ramnarayan, Chief ... with our client is an opportunity for us to ...
(Date:7/31/2014)... Loffler Companies, the leading business technology and services ... as a Microsoft Community Connections Partner of the Year ... 2014. , The Microsoft U.S. SMB Champions Club ... IT services and solutions to small and midsized business ... Champions Club member, Loffler has established a proven track ...
(Date:7/31/2014)... According to new research report "Meat Substitutes Market ... Tofu-Based Product, Tempeh, TVP, Seitan, Quorn, Others), by ... to 2019", defines and segments the global Meat ... the market value of sources, types, and categories ... driving and restraining factors for the global market ...
(Date:7/31/2014)... Angeles, California (PRWEB) July 31, 2014 ... program all year round to CEO Belina Calderon’s ... employment services and medical billing, 1Heart Caregiver Services, ... 1Heart Business Academy applauds the most recent resource ... Commerce Ambassador Glenn Bowie for sharing his expertise ...
Breaking Medicine News(10 mins):Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 3Health News:Global Bank Awards CRA with Network Infrastructure Contract 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 2Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 3Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 4
... people with history of unprotected sex to have an ... transmission.// The announcement being the first case of such ... Thursday uncovered two clusters of HIV infections, HIV-1 subtype ... government scientists. They said that both the clusters found ...
... and China's growing strengths in medical research, British Prime ... 'global medical excellence cluster' comprising universities and drugs companies. ... southeast England to protect Britain's science base and boost ... latest of measures initiated by government functionaries while citing ...
... detection of colorectal cancer were almost four times as successful ... they// were more likely to spot polyps, according to ... a thin flexible tube with a tiny camera into the ... for abnormalities, including cancerous and pre-cancerous growths. ,On ...
... anti-rejection medications for kidney transplant recipients. It is well ... ,Long-term steroid use is associated with bone ... Therefore, much effort has been made toward decreasing, withdrawing ... organ transplantation. ,A new study in Clinical ...
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... Medicine and EXACT Sciences Corporation announced today the publication// ... DNA testing. The study found that the test demonstrated ... detection across all stages of cancer, regardless of the ... study confirms that stool-based DNA technologies can achieve high ...
Cached Medicine News:Health News:Britain Plans Medical Hub To Meet India, China Challenge 2Health News:Colonoscopies Can Help Prevent Colon Cancer; Only When Done Properly 2Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:Study Results on Stool DNA Testing for Colon Cancer Announced 2
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
... Self-Cath Closed System is a latex-free ... for safe, simple catheterization designed to ... infections. It includes a 100% ... new EasyOff tear tab makes it ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Medicine Products: